Switching within the Class of IL-17 Inhibitors for the Treatment of Plaque Psoriasis: Efficacy and Safety Results from a Single-Center Study (AAD 2026) - Mar 12, 2026 - Abstract #75227; "The study suggest that performing an intraclass switch among IL-17 inhibitors is a generally effective and safe option. Xeligekimab has the potential to better meet the requirements of treat-to-target therapy for patients."
Clinical • Dermatology • Immunology • Plaque Psoriasis • Psoriasis • IL17A
|